Reach Us +1-217-403-9671
ANDA Suitability Petition Vs. 505 (B) 2 Applications | 7552
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

ANDA Suitability Petition vs. 505 (B) 2 Applications

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Pandya Hardik P

Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.008

Two routes are well known for filing the variation from the approved RLD as a generic player in the US market that is, filing an Abbreviated New Drug Application (ANDA) following the approval of Suitability Petition (SP) filing and another is filing New Drug Application (NDA) inline with 505(b)(2) of the act. The SP process is addressed in 21 CFR part 10.20 and 10.30, 314.54, 314.93. Most of the times it become confusing in selecting the appropriate route of filing and evaluating their common and uncommon requirements. Underlining information in this article helps in understating the filing requirement of each route and the way in which the US Food and Drug Administration (FDA) has recently begun using its authority for variations is critical for choosing the appropriate path. The differences between the SP and the 505(b)(2) NDA submission are also discussed in FDA.
Pandya Hardik currently pursuing his 2nd year M. Pharm in Regulatory Affairs from JSS University, Mysore. He has done his graduation from KLE?s college of pharmacy Belgaum. He has attended 63rdIPC and presented a poster on ?Regulatory Requirements for approval of a new drug in India under Section 122-E? and also attended Indo-American Pharmaceutical Regulatory Symposium- 2011 and presented a poster on ?NewAdverseevent reporting policy by FDA during clinical trials: obliging an eloquent practice!?.